Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:    
Research and development $ 15,169 $ 12,392
General and administrative 5,990 5,745
Legal settlement (2,600) 1,600
Impairments 19,092
Total operating expenses 18,559 38,829
Loss from operations (18,559) (38,829)
Other (expense) income:    
Interest income (expense), net 640 (2)
Change in fair value of derivative liabilities 12
Foreign exchange loss (65) (18)
Total other income (expense), net 575 (8)
Net loss $ (17,984) $ (38,837)
Net loss per common share:    
Net loss per common share, basic $ (1.87) $ (4.77)
Net loss per common share, diluted $ (1.87) $ (4.77)
Weighted average number of common shares, basic 9,651 8,143
Weighted average number of common shares, diluted 9,651 8,143